Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry.
Martin J BergmanPatrick ZuegerJayeshkumar PatelChristopher D SafforeIa TopuriaCristi CavanaughSiran FangJerry ClewellAlexis OgdiePublished in: Rheumatology and therapy (2022)
Findings from this study demonstrate lower disease activity among patients with PsA and AS is associated with less HCRU and lower costs over the following year.